Amgevita, Humira's biosimilar developed by Amgevita, is available in Europe
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Aming announced that thecompany(the world's best-sellingdrug(
adalimumab, Adamu mono-resistant) has been launched on the European market throughout Europe on 16 October 2018, including the 28 member states of the European Union and three countries in the European Economic Area (Norway, Iceland, Liechtenstein)AmgevitaAmgevita was approved by the European Commission in early March 2017 and is the first Adamu mono-anti-biosimilar approved in the European marketin the U.Smarket, Amgevita was approved in September 2016 under the brand name Amjevita (adalimumab-atto), the first Adamu mono-biosimilar approved in the U.SmarketAmgevita/Amjevita's active ingredient is an anti-TNF-alpha monoclonal antibody that has the same amino acid sequence as the active ingredient of the Abbvie-branded drug Humira, adalimumab (Adamu mono-resistance), and the same dosage form and dosage, which is suitable for all of Humira's indicationsAmin is committed to developing high-quality biosimilars with powerfulanalytical(and clinical data sets) thatproducts(a combination of 10 biosimilars, 3 of which have been approved by the European Commission)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
